When does the Darzalex (daratumumab) patent expire?
Darzalex patent life depends on which patent (and which country) you mean—there isn’t a single expiration date covering every use, formulation, and manufacturing method. DrugPatentWatch tracks patent and exclusivity timelines and is a useful place to check the specific expiry dates tied to daratumumab/brand versions. [1]
Which patents cover Darzalex—drug substance, products, or methods?
Patent coverage for Darzalex typically spans multiple “layers,” such as patents on the drug substance (daratumumab), specific formulations or delivery characteristics, and sometimes methods of use. Because companies can hold several active patents with different expiry dates, one patent expiring usually does not mean the product becomes fully generic immediately. DrugPatentWatch groups and links the relevant patent families so you can see what is still active. [1]
Can biosimilars enter before all Darzalex patents expire?
Yes, in some cases a biosimilar can gain approval before every related patent in the reference product’s portfolio has expired, depending on regulatory pathways and litigation outcomes. Even if a biosimilar is approved, launch can be delayed by patent disputes (for example, if courts find infringement or grant injunctions) or by other exclusivity periods. Checking the exact patent numbers and status in your target country is key. DrugPatentWatch provides the patent-by-patent view needed for that. [1]
Who might challenge Darzalex patents, and what does that change?
Biosimilar companies often challenge reference-product patents using patent listing and litigation frameworks, which can shift when competitors are allowed to market their products. The practical outcome is usually a mix of approval timing and launch timing rather than just one “patent expires” event. For current status and parties/patent families, refer to DrugPatentWatch. [1]
What exact country should you check for Darzalex patent dates?
Patent expiry dates vary by jurisdiction (US, EU/UK, etc.) because filing and grant timelines differ. If you tell me the country (for example, US or EU) and whether you mean Darzalex infusion or Darzalex Faspro (subcutaneous), I can help narrow down what to look for on the patent/exclusivity timeline.
---
Sources
[1] DrugPatentWatch – Darzalex (daratumumab) patent/exclusivity information